2021
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
Falchook G, Luke J, Strauss J, Gao X, LoRusso P, VOON P, Li C, Shaw M, Gregory R, Horn K, Gibbs J, Lineberry N, Stumpo K, Malek K, Olszanski A. A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors. Journal Of Clinical Oncology 2021, 39: tps2670-tps2670. DOI: 10.1200/jco.2021.39.15_suppl.tps2670.Peer-Reviewed Original ResearchMetastatic solid tumorsCombination armCheckpoint inhibitorsSTING agonistsNovel STING agonistSolid tumorsDose escalationEastern Cooperative Oncology Group performance status 0Anti-programmed death ligand 1 therapyDay 1Phase 1 dose-escalation studyAnti-programmed death-1Death ligand 1 therapyPerformance status 0Phase 2 doseProinflammatory tumor environmentSolid Tumors (RECIST) v.Immune checkpoint inhibitorsDose-escalation studyResponse Evaluation CriteriaInnate immune cellsPreliminary antitumor activityStandard therapeutic optionAntitumor immune mechanismsImmuno-oncology therapies
2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review Of Hematology 2017, 10: 345-364. PMID: 28277851, DOI: 10.1080/17474086.2017.1297704.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsErythropoiesis stimulating agentsMyelodysplastic syndromeLR-MDSImmunosuppressive therapyTreatment modalitiesLower-risk myelodysplastic syndromesTGF-β pathway inhibitorCombination treatment modalitiesLR-MDS patientsPromising investigational agentsSubset of patientsAvailable therapeutic modalitiesGoals of careStandard therapeutic optionPredictors of responseCurrent treatment modalitiesAcute myeloid leukemiaQuality of lifeBone marrow failureRisk assessment toolSymptom controlBlood cytopeniasInvestigational agentsTherapeutic optionsClinical behavior
2016
Network Effects and Pathways in Deep Brain Stimulation in Parkinson's Disease**Koirala N, Fleischer V, Muthuraman M, Groppa S, are with the Johannes Gutenberg university hospital, 55131, Mainz and Granert O, Deuschl G is with University clinic Schleswig-Holstein, 24105, Kiel, Germany;
Koirala N, Fleischer V, Granert O, Deuschl G, Muthuraman M, Groppa S. Network Effects and Pathways in Deep Brain Stimulation in Parkinson's Disease**Koirala N, Fleischer V, Muthuraman M, Groppa S, are with the Johannes Gutenberg university hospital, 55131, Mainz and Granert O, Deuschl G is with University clinic Schleswig-Holstein, 24105, Kiel, Germany;. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2016, 2016: 5533-5536. PMID: 28269510, DOI: 10.1109/embc.2016.7591980.Peer-Reviewed Original ResearchConceptsSupplementary motor areaDeep brain stimulationSTN-DBSParkinson's diseaseDiffusion tensor imagingBrain stimulationProbabilistic tractographyActive DBS contactsPostoperative clinical outcomesPrimary motor cortexStandard therapeutic optionIdiopathic Parkinson's diseaseCortico-spinal tractSubcortical seedsClinical outcomesTherapeutic optionsDBS contactsMotor cortexDBS treatmentUniversity HospitalSubthalamic nucleusMotor areaPremotor regionsStimulation siteTensor imaging
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply